嵌合抗原受体
免疫疗法
癌症免疫疗法
癌症研究
T细胞受体
免疫学
免疫原性
T细胞
细胞毒性T细胞
链霉菌
离体
细胞疗法
癌症
肿瘤微环境
免疫系统
过继性细胞移植
抗原
CD137
肿瘤抗原
CD8型
医学
免疫检查点
生物
癌细胞
体内
干细胞
细胞生物学
内科学
生物技术
摘要
The clinical outcome of the traditional adoptive cancer immunotherapy approaches involving the administration of donor-derived immune effectors, expanded ex vivo , has not met expectations. This could be attributed, in part, to the lack of sufficient high-avidity antitumor T-cell precursors in most cancer patients, poor immunogenicity of cancer cells, and the technological limitations to generate a sufficiently large number of tumor antigen-specific T cells. In addition, the host immune regulatory mechanisms and immune homeostasis mechanisms, such as activation-induced cell death (AICD), could further limit the clinical efficacy of the adoptively administered antitumor T cells. Since generation of a sufficiently large number of potent antitumor immune effectors for adoptive administration is critical for the clinical success of this approach, recent advances towards generating customized donor-specific antitumor-effector T cells by engrafting human peripheral blood-derived T cells with a tumor-associated antigen-specific transgenic T-cell receptor (TCR) are quite interesting. This manuscript provides a brief overview of the TCR engineering-based cancer immunotherapy approach, its advantages, and the current limitations.
科研通智能强力驱动
Strongly Powered by AbleSci AI